Decisión del Panel Administrativo nº D2017-0262 of WIPO Arbitration and Mediation Center, March 31, 2017 (case Sanofi v. Contact Privacy Inc. Customer 1241050366 / Name Redacted)
| Resolution Date | March 31, 2017 |
| Issuing Organization | WIPO Arbitration and Mediation Center |
| Decision | Transfer |
| Dominio | Generic Domains |
The Complainant is Sanofi of Paris, France, represented by Selarl Marchais & Associés, France.
The Respondent is Contact Privacy Inc. Customer 1241050366 of Toronto, Ontario, Canada / Name Redacted.[1 ]
The disputed domain name [sanoficareer.com] is registered with Google Inc. (the “Registrar”).
The Complaint was filed with the WIPO Arbitration and Mediation Center (the “Center”) on February 10, 2017. On the same date, the Center transmitted by email to the Registrar a request for registrar verification in connection with the disputed domain name. On the same date, the Registrar transmitted by email to the Center its verification response disclosing registrant and contact information for the disputed domain name which differed from the named Respondent and contact information in the Complaint. The Center sent an email communication to the Complainant on February 13, 2017 providing the registrant and contact information disclosed by the Registrar, and inviting the Complainant to submit an amendment to the Complaint. The Complainant filed an amendment to the Complaint on February 20, 2017.
The Center verified that the Complaint together with the amendment to the Complaint satisfied the formal requirements of the Uniform Domain Name Dispute Resolution Policy (the “Policy” or “UDRP”), the Rules for Uniform Domain Name Dispute Resolution Policy (the “Rules”), and the WIPO Supplemental Rules for Uniform Domain Name Dispute Resolution Policy (the “Supplemental Rules”).
In accordance with the Rules, paragraphs 2 and 4, the Center formally notified the Respondent of the Complaint, and the proceedings commenced on February 21, 2017. In accordance with the Rules, paragraph 5, the due date for Response was March 13, 2017. A Response from the named Respondent was received by the Center on March 7, 2017. The Center notified the Parties the commencement of the Panel Appointment process on March 14, 2017.
The Center appointed J. Nelson Landry as the sole panelist in this matter on March 21, 2017. The Panel finds that it was properly constituted. The Panel has submitted the Statement of Acceptance and Declaration of Impartiality and Independence, as required by the Center to ensure compliance with the Rules, paragraph 7.
Sanofi is a French multinational pharmaceutical company ranking among the world’s largest pharmaceutical companies by research, development and prescription of pharmaceutical products. The Complainant is settled in more than 100 countries on all continents employing 110,000 people. In 2015, it invested over EUR 5 billion in research and development and its net sales were of EUR 39 billion in that year. It is a leading pharmaceutical company in seven major therapeutic areas namely cardiovascular, thrombosis, metabolic disorders, oncology, central nervous system, internal medicine and vaccines.
The Complainant is the owner of numerous SANOFI trademarks under four groups, SANOFI (+device), SANOFI, Sanofi and Sanofi (+device). First, each are registered in France, the earliest one being French Trademark No. 1482708 SANOFI (registered on August 11, 1998, in international classes 1, 3, 4, 5, 10, 16, 25, 28 and 31); second, three are registered in the European Union, SANOFI first since 1997; third, each of the four are registered as an International trademark, the first one on September 25, 1992; then SANOFI was registered in the United States of America on July 24, 2012, the country of residence of the Respondent (herein the “SANOFI Trademarks”).
Furthermore, the Complainant has registered and is the owner of 11 different domain names, all comprised of the term “sanofi” and a Top-Level Domain (“TLD”), including [sanofi.com]...
To continue reading
Request your trial